{"name":"GCS Ramsay Santé pour l'Enseignement et la Recherche","slug":"gcs-ramsay-sant-pour-l-enseignement-et-la-recherche","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Intravenous lidocaine administration","genericName":"Intravenous lidocaine administration","slug":"intravenous-lidocaine-administration","indication":"Other","status":"phase_1"},{"name":"C1 Inhibitor Human","genericName":"C1 Inhibitor Human","slug":"c1-inhibitor-human","indication":"Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis","status":"marketed"},{"name":"Neuroleptanalgesia","genericName":"Neuroleptanalgesia","slug":"neuroleptanalgesia","indication":"Other","status":"phase_1"},{"name":"Rachianesthesia","genericName":"Rachianesthesia","slug":"rachianesthesia","indication":"Other","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"standard pain relievers","genericName":"standard pain relievers","slug":"standard-pain-relievers","indication":"Mild to moderate pain","status":"marketed"}]}],"pipeline":[{"name":"Intravenous lidocaine administration","genericName":"Intravenous lidocaine administration","slug":"intravenous-lidocaine-administration","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"standard pain relievers","genericName":"standard pain relievers","slug":"standard-pain-relievers","phase":"marketed","mechanism":"Standard pain relievers work by inhibiting cyclooxygenase (COX) enzymes or blocking pain signal transmission to reduce pain perception.","indications":["Mild to moderate pain","Fever","Inflammation-related pain conditions"],"catalyst":""},{"name":"C1 Inhibitor Human","genericName":"C1 Inhibitor Human","slug":"c1-inhibitor-human","phase":"marketed","mechanism":"C1 Inhibitor Human is a plasma-derived protein replacement therapy that restores deficient or dysfunctional C1 esterase inhibitor to prevent excessive bradykinin generation and control hereditary angioedema attacks.","indications":["Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis"],"catalyst":""},{"name":"Neuroleptanalgesia","genericName":"Neuroleptanalgesia","slug":"neuroleptanalgesia","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rachianesthesia","genericName":"Rachianesthesia","slug":"rachianesthesia","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":2,"marketed":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}